Mouse models and studies performed on fixed bone marrow (BM) specimens obtained from patients with multiple myeloma (MM) suggest that plasma cell growth is dependent on endothelial cell (EC) proliferation within the BM microenvironment. In order to assess whether EC overgrowth in MM reflects a spontaneous in vitro angiogenesis, BM mononucleated cells from 13 untreated (UT) MM, 20 treated (11 with melphalan and nine with DAV schedule) MM, eight patients with monoclonal gammopathy of uncertain significance (MGUS) and eight controls were seeded in an unselective medium to assess EC proliferation. Furthermore, the influence of IL6 on the EC growth was investigated. Endothelial colonies (CFU-En) appeared as small clusters, formed by at least 100 slightly elongated and sometimes bi-nucleated cells expressing factor VIII, CD31 and CD105 (endoglin). The CFU-En mean number/10 6 BM mononucleated cells in untreated MM samples (2.07 s.d. ± 1.3) was significantly higher than in normal BM (0.28 ± 0.48), while no difference was seen between normal BM and MGUS (0.28 ± 0.54). Interestingly, the mean number of CFU-En in the DAV group (1.88 ± 1.6) did not differ from the UT, while it was found to be lower in the melphalan group (0.31 ± 0.63). The addition of anti-IL6 monoclonal antibody induced a reduction of both the plasma cells in the supernatant and the CFU-En number. This study describes a rapid and feasible assay providing support for the association between EC and plasma cells further suggesting that the in vitro angiogenesis process may parallel that observed in vivo. Leukemia (2001) 15, 171-176. 
Introduction
In solid neoplasm endothelial cell (EC) proliferation constitutes an essential part of the tumor burden enlargement representing the essential steps towards the formation of metastasis. 1 As far as the hematological malignancies are concerned, several studies have stressed the role of angiogenesis in multiple myeloma (MM), [2] [3] [4] non-Hodgkin lymphoma 5 and acute leukemia. 6, 7 The study of MM in mouse models has shown that plasma cell growth is dependent on EC proliferation within the bone marrow (BM) microenvironment. 8, 9 Recently, the microvessel density (MVD) of MM BM cells, as assessed by anti-factor-VIII monoclonal antibody (MoAb) staining Correspondence: GL Castoldi, Section of Hematology, Department of Medical Sciences and Advanced Therapies, University of Ferrara, Via Savonarola n. 9, 44100 Ferrara, Italy; Fax: +390532. 212142 Received 23 March 2000; accepted 13 September 2000 method, was found to be significantly increased compared with that of control samples. 2, 3 A statistically significant correlation between endothelial MVD and proliferative capabilities of malignant plasma cells (MPC) has also been shown, using a similar technique. 2, 4 Based on these findings, we judged it appropriate to examine angiogenesis in MM by evaluating the endothelial colonies (CFU-En) in cultured bone marrow mononuclear cells (BMMNC) from MM and monoclonal gammopathy of uncertain significance (MGUS) patients. In the attempt to create an in vitro steady-state marrow microenvironment, the addition of specific media for EC proliferation was deliberately avoided. We have also examined in this system the effect of the addition of monoclonal antibody anti-IL6, which is known to prolong survival and proliferation of MPC in vitro and also to promote angiogenesis.
10,11

Patients and methods
Patients
Thirty-three consecutive MM patients admitted to the Hematology Institute of Ferrara were included in this study. The median age was 63.1 (range 36-86) with a male/female ratio of 17/16. Patients were classified according to Durie and Salmon criteria. 12 The patients were also evaluated with consideration of their disease state: in plateau phase (n = 12), with stable (for at least 3 months) monoclonal component (MC), bone marrow infiltration (BMI), C-reactive protein (CRP), ␤2-microglobulin (␤2m) and hemoglobin, or in progression when expressing a modification of these parameters. Thirteen patients were studied at the onset of their disease and were untreated (UT); the remaining (n = 11) were treated either with melphalan (10 mg/m 2 1-4 days) and prednisone (60 mg/m 2 1-4 days) 13 (MP) or (n = 9) according to the DAV protocol (adriamycin 35 mg/m 2 , vincristine 1.5 mg/m 2 both i.v. on day 1 and dexamethasone 40 mg/day i.m. 1-5 days). 14 The bone marrow biopsy was performed after 2 months from the last cycle of therapy, in the DAV group (median; range 1-16) and after 3 months (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) in the MP group. Patients in the MP group have been treated with 12 cycles (4-26) while in the DAV group patients received six therapy cycles (4) (5) (6) (7) (8) .
Eight patients with MGUS were also considered with a 
Cell cultures
The BM specimens were obtained, after informed consent, by aspiration with Jamshidi needle; 3 ml from each fresh sample were gently passaged through a 22-gauge needle in order to homogenize the BM spicules. 15 Cultures were performed in triplicate. At weekly intervals, half of the supernatant medium and suspension cells were removed and replaced with fresh medium. At day 15, using an inverted microscope (10×, Wilovert-Will, Wetzlar, Germany), CFU-En detection was carried out.
In the samples taken from seven UT patients in which a consistent EC proliferation was noticed, a second culture condition was introduced, composed of M199 Glutamax I (Gibco BRL, Life Technology, Paisley, UK) supplemented with 20% fetal calf serum (StemCell Technologies), 1% penicillin/streptomycin and 1% l-glutamine (Hyclone Europe) and incubated as previously reported. 16 In order to assess the clonogenic capabilities, ECs were sub-cloned and plated in M199 Glutamax I with 20% FCS in 60-mm dishes with a printed grid which allowed an evaluation of clonogenic potential of the single EC.
Immunophenotypic characteristics of cultured cells
Cultured cells were studied using an immunohistochemical technique in combination with either polyclonal or monoclonal antibodies. These studies were performed in situ after medium removal: briefly, Petri dishes were washed in prewarmed TBS (pH 7.6), air-dried and fixed in acetone and methanol 1:1 for 1 min. Negative controls with isotypematched non-relevant MoAbs (mouse IgG1, IgG2a, IgM) were tested in all experiments. Fixed slides were incubated for 10 min with normal rabbit serum (DAKO, Milan, Italy) and then washed in TBS. The dishes with primary MoAb were incubated for 30 min. Rabbit anti-mouse immunoglobulins (DAKO) and APAAP complex (DAKO) were added, at each step for a 30-min incubation time. Alkaline phosphatase substrate was added and incubated for 15 min. The slides were washed in TBS, contrasted with hematoxylin, mounted in a suitable aqueous medium and examined under microscope (Diaplan Microscope, Leitz, Germany). 
Anti-IL6 treatment of the BM cultures
Samples obtained from seven untreated MM patients were tested using monoclonal antibodies against hIL6 (mouse antihuman IgG3; Genzyme, Cambridge, MA, USA). Briefly, mouse anti-human IL6 at a final concentration of 20 g/ml was dialysed against LTC medium and re-fed every 5 days. Cultures were assessed in duplicate and EC evaluation and CFU-En scoring were performed after 15 days as for the untreated samples.
Statistical analysis
The results were expressed as the mean ± standard deviation (± s.d.). CFU-En frequencies and clinical and biological parameters were compared using non-parametric statistics (Wilcoxon test). Data were computed with the Systat for Window.
Results
Cell culture
Starting from the first week of culture, the growth of small groups of ECs (mean cell number 10; range 7-24) was noticed ( Figure 1a and b) ; on morphological grounds, they appeared as round slightly elongated and sometimes bi-nucleated cells (Figure 1c ) positive for factor VIII MoAb, CD31 and CD105 (Figure 1d-g ). At the beginning, EC proliferation started within the adherent fraction mainly composed by phagocytic mononucleated cells (CD14 Figure 1h) ; at day 15 endothelial colonies became larger allowing a more feasible microscopical evaluation. A cell cluster of at least 100 cells formed each colony.
Even though the medium used was not selective for endothelial growth, it allows an 'in vitro' preservation of reciprocal relationship between MPC and the bone marrow microenvironment. However, it should be outlined that after a longer incubation time (more than 15 days), the proliferating fibroblasts (Collagen I-II-III+/CD68 + ) usually prevented the further expansion of CFU-En. When colony number appeared consistent, the introduction of the more selective M199 medium allowed a discrete increase of the size of CFU-En, although a complete confluence was never reached and the colony numbers never increased, mainly due to the absence of selective growing factors. Even though the assessment of clonogenic capabilities revealed a low potential, a single cell re-plated gave rise to 5-10 cells, in the absence of specific growth media. Interestingly, mononucleated cells (mainly represented by MPC in the MM samples), never attached to the CFU-En, while most of the fibroblast clones usually appeared to be covered by MPC, often showing the presence of proliferation niches within the stromal adherent layer. Furthermore, a delay in the growth pattern of the stromal layer was observed, and its confluence was never reached.
Assessment of CFU-En in comparison with chemotherapy
As shown in Figure 2a , the mean number of endothelial colonies in MM patients was significantly (P = 0.01) higher than in the control group. The same difference was maintained when MGUS and MM patients were compared (P = 0.02), while no difference was observed between MGUS patients and normal bone marrow. The CFU-En overall number in MM is 5.1-fold higher than that in control and MGUS samples.
In the attempt to investigate the possible effect of the different therapeutic regimens on the angiogenesis process in MM, patients were subgrouped on the basis of the chemotherapeutic regimens administered (Figure 2b) . Interestingly, the differences observed resulted even more consistent, being CFU-En mean number in UT group 7.3-fold more than control MGUS. Treated patients showed a lower CFU-En number 1.02 (mean; s.d. ± 1.1; P = 0.003) than untreated patients. This was mainly attributed to the very low value of CFU-En number in the MP group (0.31 ± 0.6; P = 0.009) while the number of CFU-En in the DAV group was comparable (1.87 ± 1.1) to that observed in samples from UT patients. The treated population was further divided in two different subgroups, including patients treated with more or less than six cycles, respectively. The first group (Ͼ6 cycles), mainly enrolled in the MP group, showed a lower incidence of CFU-En (0.3 ± 0.6) than the second (Ͻ6 cycles) (1.9 ± 1.3; P = 0.01). No differences were noticed in the number of CFU-En when the time lapse after the last chemotherapy cycle (time Ͻ2 month: 0.95 ± 0.9; time Ͼ2 months: 1.12 ± 1.6) was considered.
CFU-En value and clinical biological aspects
Several clinical and biological characteristics (stage of the disease, MC, CRP, ␤2m and BMI) were considered in the attempt to clarify the relationship between these parameters and in vitro angiogenesis. Considering the state of the disease (Figure  2c ), the number of CFU-En appeared significantly reduced in the plateau phase (0.54 ± 0.78) compared either with that at diagnosis (P = 0.007) or with that during active disease. An increase of CFU-En number was shown in the progression phase of the disease (1.75 ± 1.38; P = 0.02). No statistically significant correlation was observed between the number of CFU-En and single laboratory parameters, although elevated levels of ␤2-microglobulin (Ͼ6 mg/l), or CRP (Ͼ1 mg/l) and especially MC (у40 g/l) were associated with a higher CFUEn number. Interestingly, bone marrow infiltration (BMI) by MPC did not affect CFU-En count so that a cut-off percentage of 20% did not discriminate between low or high value of CFU-En (Ͼ20%: 1.4 ± 1.3; Ͻ20%: 1.7 ± 1.2; not significant).
Discussion
ECs represent no more than 1-2% of BM cells 17 and to date an in vitro assay for the analysis and quantitation of EC colonies is still lacking. The establishment of human BM-derived EC cultures has been considered particularly difficult because of the very small numbers of these cells present in BM samples so that large volumes (40 ml) of BM specimens are needed. 18 Furthermore, positive selection systems with the use of Ulex Europaeus-1 agglutinin (UEA-1) and selective culture condition appear indispensable to enrich EC fraction and obtain functional endothelial monolayers. 16, 18 In this paper, we have studied the spontaneous growth of EC in patients with monoclonal gammopathies in an attempt to understand if the high vascularization already observed in fixed BM biopsies 2,3 as well as in mouse models 8, 9 could also be detected in vitro by using an unselective endothelial cell culture assay. The microscopic and immunohistochemical evaluation of CFU-En number that was present in the different samples has provided a direct measurement of the angiogenic potential of BM cells. Our culture method is somehow similar to that of bone marrow fibroblast precursor evaluation (CFU-F) and clonogenic colony assay of hemopoietic progenitors, 19, 20 and it seems to be rapid and feasible, allowing an assessment of the interactions between EC and hemopoietic malignant cells.
In contrast to what was reported by Masek and Sweetenham, 16 who found two different types of ECs in their BM culture selecting ECs with UEA I, we were able to isolate only one type of EC from MM samples, in the context of an adherent layer mainly composed of spindle-shaped fibroblast cells (FVIII negative). This difference may be due to our unselective culture conditions, without additional specific media for EC proliferation. Alternatively, it could be explained by the fact that marrow stromal cells also had receptors for UEA1, 21 thus the presence of contaminating stromal cells in their culture system cannot be excluded.
Our result of an about five-fold higher number of CFU-En in MM than MGUS and controls is comparable to the increased level of BM vascularization in MM patients as detected by MVD. 2, 3 We have also observed that the numbers of CFU-En either at diagnosis or during disease progression were respectively seven-fold and six-fold higher than MGUS, thus confirming previous data showing an increased vascular density during the active phases of MM. 2 Furthermore, melphalan-treated patients had a significantly lower number of CFU-En than those treated with the DAV regimen. This finding is of note since melphalan is known to induce damage of the hemopoietic progenitor cell compartment, 22, 23 but no data have been so far available on the effects of this drug on BM ECs. Thus, the lower increase in the CFU-En mean value in patients in the plateau phase although consistent with a stable disease, may also be due to the fact that 8/12 MM patients in plateau phase were previously treated with a melphalanbased protocol.
Recently, it has been reported that a non-cytotoxic dose of vinca alkaloid retains in vitro anti-angiogenic properties as assessed by testing, with inhibition proliferation assay, umbilical cord-derived ECs. 24 However, in our study, samples obtained from patients receiving the DAV schedule therapy, which contains a vinca alkaloid, display a number of CFU-En comparable to that of the untreated group. It is well known that IL6 levels play a pivotal role in the pathogenesis of MM, allowing survival and proliferation of MPC, 25, 26 It has been suggested that IL6 could influence the angiogenesis process. 11 Our findings suggest that the use of anti-hIL6 MoAb can not only affect MPC survival as expected but also induce a reduction of CFU-En numbers, lending further support to the proposed IL6 involvement in the angiogenesis process.
In conclusion, we describe an in vitro culture evaluation of angiogenesis in MM, which potentially may be applied to other hematological diseases. The good correlation we found between the CFU-En number and the progression phase of the disease makes this assay of clinical utility. Moreover, this assay provides a sort of steady-state marrow microenvironment which is not altered by addition of specific media for EC proliferation and may thus be exploited to study the influence of various factors (cytokine, viruses etc) and drugs on the interaction between ECs and MPC in the BM of MM patients.
